Tooluniverse Gwas Drug Discovery

GWAS-to-Drug Target Discovery

Transform genome-wide association studies (GWAS) into actionable drug targets and repurposing opportunities.

IMPORTANT: Always use English terms in tool calls. Respond in the user's language.

---

Overview

This skill bridges genetic discoveries from GWAS with drug development by:

1. Identifying genetic risk factors - Finding genes associated with diseases 2. Assessing druggability - Evaluating which genes can be targeted by drugs 3. Prioritizing targets - Ranking candidates by genetic evidence strength 4. Finding existing drugs - Discovering approved/investigational compounds 5. Identifying repurposing opportunities - Matching drugs to new indications

Key insight: Targets with genetic support have 2x higher probability of clinical approval (Nelson et al., Nature Genetics 2015).

Reasoning Strategy

GWAS-to-drug translation succeeds when you think causally. A genetic association provides causal direction that observational data cannot: if a loss-of-function variant protects against disease, an inhibitor of that gene's product is the hypothesis to test. The direction of effect (LOF vs. GOF) determines whether you need an inhibitor or an agonist — get this wrong and the drug works backwards. GWAS effect sizes are small (odds ratios of 1.1–1.5 are typical), but the drug effect may be much larger or smaller than the genetic effect; the genetic signal validates the target, not the dose. Always integrate multiple lines of evidence (eQTL colocalization, pQTL, L2G score) before committing to a target, because many GWAS variants tag the causal gene only indirectly.

LOOK UP DON'T GUESS: Do not assume which gene a GWAS variant implicates — use OpenTargets_get_variant_credible_sets or gwas_get_associations_for_snp to get the actual mapped gene and L2G score. Do not guess the direction of effect, odds ratio, or whether a drug already exists for the target; always query the tools.

---

Workflow Steps

Step 1: GWAS Gene Discovery

Input: Disease/trait name (e.g., "type 2 diabetes", "Alzheimer disease")

Process: Query GWAS Catalog for associations, filter by significance (p < 5x10^-8), map variants to genes, aggregate evidence.

Tools:

• gwas_get_associations_for_trait - Get associations by disease
• gwas_search_associations - Flexible search
• gwas_get_associations_for_snp - SNP-specific associations
• OpenTargets_search_gwas_studies_by_disease - Curated GWAS data
• OpenTargets_get_variant_credible_sets - Fine-mapped loci with L2G predictions

Step 2: Druggability Assessment

Input: Gene list from Step 1

Process: Check target class, assess tractability, evaluate safety, check for tool compounds or structures.

Tools:

• OpenTargets_get_target_tractability_by_ensemblID - Druggability assessment
• OpenTargets_get_target_classes_by_ensemblID - Target classification
• OpenTargets_get_target_safety_profile_by_ensemblID - Safety data
• OpenTargets_get_target_genomic_location_by_ensemblID - Genomic context

Step 3: Target Prioritization

Scoring Formula:

Target Score = (GWAS Score x 0.4) + (Druggability x 0.3) + (Clinical Evidence x 0.2) + (Novelty x 0.1)

Rank targets by composite score. Generate target dossiers.

Step 4: Existing Drug Search

Process: Search drug-target associations, find approved drugs and clinical candidates, get MOA and indication data.

Tools:

• OpenTargets_get_associated_drugs_by_disease_efoId - Known drugs for disease
• OpenTargets_get_drug_mechanisms_of_action_by_chemblId - Drug MOA
• ChEMBL_get_target_activities - Bioactivity data
• ChEMBL_get_drug_mechanisms / ChEMBL_search_drugs - Drug data

Step 5: Clinical Evidence & Safety

Tools:

• FDA_get_adverse_reactions_by_drug_name - Safety data
• FDA_get_active_ingredient_info_by_drug_name - Drug composition
• OpenTargets_get_drug_warnings_by_chemblId - Drug warnings

Step 6: Repurposing Opportunities

Match drug targets to new disease genes, assess mechanistic fit, check contraindications, estimate repurposing probability.

---

Quick Start

from tooluniverse import ToolUniverse
tu = ToolUniverse(use_cache=True)
tu.load_tools()

# Step 1: Get GWAS associations (use disease_trait not trait; no p_value_threshold param)
associations = tu.tools.gwas_get_associations_for_trait(disease_trait="type 2 diabetes")

# Step 2: Assess druggability (ensemblId lowercase d)
tractability = tu.tools.OpenTargets_get_target_tractability_by_ensemblID(ensemblId="ENSG00000148737")

# Step 3: Find existing drugs per target via DGIdb (OpenTargets drug query may return HTTP 400)
drugs = tu.tools.DGIdb_get_drug_gene_interactions(genes=["TCF7L2"])

---

All Tools by Category

GWAS & Genetics:

• gwas_get_associations_for_trait / gwas_search_associations / gwas_get_associations_for_snp
• OpenTargets_search_gwas_studies_by_disease / OpenTargets_get_variant_credible_sets

Target Assessment:

• OpenTargets_get_target_tractability_by_ensemblID / OpenTargets_get_target_classes_by_ensemblID
• OpenTargets_get_target_safety_profile_by_ensemblID / OpenTargets_get_target_genomic_location_by_ensemblID

Drug Discovery:

• OpenTargets_get_associated_drugs_by_disease_efoId / OpenTargets_get_drug_mechanisms_of_action_by_chemblId
• ChEMBL_get_target_activities / ChEMBL_get_drug_mechanisms / ChEMBL_search_drugs

Safety & Clinical:

• FDA_get_adverse_reactions_by_drug_name / FDA_get_active_ingredient_info_by_drug_name
• OpenTargets_get_drug_warnings_by_chemblId

Literature:

• PubMed_search_articles / EuropePMC_search_articles / ClinicalTrials_search_studies

---

Best Practices

1. Multi-ancestry GWAS: Include trans-ethnic meta-analyses for robust signals 2. Functional validation: Confirm with eQTL, pQTL, colocalization analysis 3. Network analysis: Group GWAS hits by pathway (KEGG, Reactome) 4. Safety assessment: Check gnomAD pLI, GTEx expression, PharmaGKB 5. Batch operations: Use tu.run_batch() for parallel queries across targets

---

Parameter Gotchas

Interpretation: From GWAS Hit to Drug Target

GWAS Signal Strength Assessment

Target Prioritization Decision Tree

After identifying GWAS-linked genes, rank them by answering:

1. Is the gene druggable? (DGIdb category: kinase/GPCR/ion channel = yes; transcription factor/scaffold = harder)

• If approved drug exists → REPURPOSING opportunity (fastest path)
• If druggable but no drug → NOVEL TARGET (standard drug discovery)
• If not druggable → consider antisense/PROTAC/genetic medicine

2. Is the genetic direction clear?

• LOF variants increase disease risk → need an AGONIST or gene therapy
• GOF variants increase disease risk → need an INHIBITOR (typical small molecule)
• Direction unclear → need functional studies before drug design

3. What's the effect size? (Odds ratio from GWAS)

• OR > 2.0: strong effect, likely penetrant → Mendelian-like, high confidence
• OR 1.2-2.0: moderate, common in complex disease → validate with independent data
• OR < 1.2: small effect → may not be clinically meaningful alone

4. Is there clinical precedent?

• Drug for same target approved for ANY disease → safety data exists → lower risk
• Drug in clinical trials → partial de-risking
• No precedent → full de novo development risk

---

Troubleshooting

---

Reference Files

• REFERENCE.md - Detailed concepts, druggability tiers, clinical translation, limitations, ethics
• EXAMPLES.md - Use cases (Huntington's, Alzheimer's, diabetes) with success stories
• REPORT_TEMPLATE.md - Output report template with scoring criteria
• PROCEDURES.md - Step-by-step implementation procedures
• QUICK_START.md - Quick start guide
• Related skills: tooluniverse-drug-repurposing, disease-intelligence-gatherer, tooluniverse-sdk

GWAS-to-Drug Discovery Examples

Use Case 1: Novel Target Discovery for Rare Disease

Scenario: Identify druggable targets for Huntington's disease

Steps: 1. Get GWAS hits for Huntington's -> HTT, PDE10A, MSH3 2. Assess druggability -> PDE10A (phosphodiesterase) = high 3. Find existing PDE10A inhibitors -> Multiple tool compounds 4. Recommendation: Develop selective PDE10A inhibitor

Clinical Context:

• HTT (huntingtin) = difficult to drug (large, scaffold protein)
• PDE10A = modifier gene, GPCR-coupled, small molecule tractable
• Precedent: PDE5 inhibitors (sildenafil) already approved

Use Case 2: Drug Repurposing for Common Disease

Scenario: Find repurposing opportunities for Alzheimer's disease

Steps: 1. Get GWAS targets -> APOE, CLU, CR1, PICALM, BIN1, TREM2 2. Find drugs targeting these -> Anti-inflammatory drugs (CR1, TREM2) 3. Match approved drugs -> Anakinra (IL-1R antagonist) 4. Rationale: TREM2 links inflammation to neurodegeneration

Example Output:

Repurposing Candidate: Anakinra
- Target: IL-1R -> affects TREM2 pathway
- Current use: Rheumatoid arthritis (approved)
- AD rationale: 3 GWAS genes in immune pathway
- Clinical phase: Phase II trial in progress
- Safety: Known profile, subcutaneous injection

Use Case 3: Target Validation for Existing Drug Class

Scenario: Validate new diabetes targets related to GLP-1 pathway

Steps: 1. Get T2D GWAS genes -> TCF7L2, PPARG, KCNJ11, GLP1R 2. GLP1R validated -> Existing drug class (semaglutide, liraglutide) 3. Check related genes -> GIP, GIPR (glucose-dependent insulinotropic polypeptide) 4. Outcome: Dual GLP-1/GIP agonists (tirzepatide, approved 2022)

Success Stories

• PCSK9 (cholesterol) -> Alirocumab, Evolocumab (approved 2015)
• IL-6R (rheumatoid arthritis) -> Tocilizumab (approved 2010)
• CTLA4 (autoimmunity) -> Abatacept (approved 2005)
• CFTR (cystic fibrosis) -> Ivacaftor (approved 2012)

Genetic Evidence Doubles Success Rate: Targets with genetic support have 2x higher probability of clinical approval (Nelson et al., Nature Genetics 2015).

GWAS-to-Drug Discovery: Detailed Procedures

Workflow Step Details

Step 1: GWAS Gene Discovery

Input: Disease/trait name (e.g., "type 2 diabetes", "Alzheimer disease")

Process:

• Query GWAS Catalog for associations
• Filter by significance threshold (p < 5x10^-8)
• Map variants to genes (nearest, eQTL, fine-mapping)
• Aggregate evidence across studies

Output: List of genes with genetic support

Step 2: Druggability Assessment

Input: Gene list from Step 1

Process:

• Check target class (GPCR, kinase, ion channel, etc.)
• Assess tractability (antibody, small molecule)
• Evaluate safety (expression profile, essentiality)
• Check for tool compounds or crystal structures

Output: Druggability score (0-1) + modality recommendations

Scoring Formula:

Target Score = (GWAS Score x 0.4) + (Druggability x 0.3) + (Clinical Evidence x 0.2) + (Novelty x 0.1)

Step 3: Target Prioritization

Input: Genes with GWAS + druggability data

Process:

• Calculate composite score: genetic evidence x druggability
• Rank targets by score
• Add qualitative factors (novelty, competitive landscape)
• Generate target dossiers

Step 4: Existing Drug Search

Input: Prioritized target list

Process:

• Search drug-target associations (ChEMBL, DGIdb)
• Find approved drugs, clinical candidates, tool compounds
• Get mechanism of action, indication, phase
• Check for off-label use or failed trials

Step 5: Clinical Evidence

Input: Drug candidates

Process:

• Check clinical trial history (ClinicalTrials.gov)
• Review safety profile (FDA labels, adverse events)
• Assess pharmacology (PK/PD, formulation)
• Evaluate regulatory path

Step 6: Repurposing Opportunities

Input: Approved drugs + new disease associations

Process:

• Match drug targets to new disease genes
• Assess mechanistic fit (agonist vs antagonist)
• Check contraindications
• Estimate repurposing probability

Repurposing Score:

• Genetic overlap: Gene targeted by drug = gene implicated in new disease
• Clinical feasibility: Dosing, route, safety profile compatible
• Regulatory path: Faster approval (Phase II vs Phase I)

Use Cases

Use Case 1: Novel Target Discovery for Rare Disease

Scenario: Identify druggable targets for Huntington's disease

Steps: 1. Get GWAS hits for Huntington's -> HTT, PDE10A, MSH3 2. Assess druggability -> PDE10A (phosphodiesterase) = high 3. Find existing PDE10A inhibitors -> Multiple tool compounds 4. Recommendation: Develop selective PDE10A inhibitor

Clinical Context:

• HTT (huntingtin) = difficult to drug (large, scaffold protein)
• PDE10A = modifier gene, GPCR-coupled, small molecule tractable
• Precedent: PDE5 inhibitors (sildenafil) already approved

Use Case 2: Drug Repurposing for Common Disease

Scenario: Find repurposing opportunities for Alzheimer's disease

Steps: 1. Get GWAS targets -> APOE, CLU, CR1, PICALM, BIN1, TREM2 2. Find drugs targeting these -> Anti-inflammatory drugs (CR1, TREM2) 3. Match approved drugs -> Anakinra (IL-1R antagonist) 4. Rationale: TREM2 links inflammation to neurodegeneration

Example Output:

Repurposing Candidate: Anakinra
- Target: IL-1R -> affects TREM2 pathway
- Current use: Rheumatoid arthritis (approved)
- AD rationale: 3 GWAS genes in immune pathway
- Clinical phase: Phase II trial in progress
- Safety: Known profile, subcutaneous injection

Use Case 3: Target Validation for Existing Drug Class

Scenario: Validate new diabetes targets related to GLP-1 pathway

Steps: 1. Get T2D GWAS genes -> TCF7L2, PPARG, KCNJ11, GLP1R 2. GLP1R validated -> Existing drug class (semaglutide, liraglutide) 3. Check related genes -> GIP, GIPR (glucose-dependent insulinotropic polypeptide) 4. Outcome: Dual GLP-1/GIP agonists (tirzepatide, approved 2022)

Druggability Assessment Deep Dive

Target Classes (by Druggability)

Tier 1: High Druggability

• GPCRs (33% of approved drugs) - Extracellular binding, established chemistry
• Kinases (18% of approved drugs) - ATP-competitive inhibitors, allosteric sites
• Ion channels (15% of approved drugs) - Blocking/opening channels
• Nuclear receptors - Ligand-binding domains

Tier 2: Moderate Druggability

• Proteases - Active site inhibitors
• Phosphatases - Challenging selectivity
• Epigenetic targets - Readers, writers, erasers

Tier 3: Difficult to Drug

• Transcription factors - No obvious binding pocket
• Scaffold proteins - Large, flat surfaces
• RNA targets - Emerging modality

Modality Selection

Small Molecules: Intracellular proteins, enzymes; oral bioavailability, CNS penetration Antibodies: Extracellular proteins, receptors; high specificity, long half-life; no CNS Antisense/RNAi: mRNA (any gene); sequence-specific; delivery challenges, liver-centric Gene Therapy: Genetic defects; one-time treatment; immunogenicity concerns

Quick Start Guide: GWAS-to-Drug Target Discovery

Get started with drug target discovery from GWAS data in minutes.

Table of Contents

1. Installation 2. Basic Usage - Python SDK 3. Basic Usage - MCP 4. Example 1: Alzheimer's Disease Targets 5. Example 2: Type 2 Diabetes Repurposing 6. Example 3: Target Prioritization 7. Common Patterns 8. Troubleshooting

Installation

Prerequisites

# Install ToolUniverse
pip install tooluniverse

# Or from source
git clone https://github.com/example/tooluniverse.git
cd tooluniverse
pip install -e .

Verify Installation

from tooluniverse import ToolUniverse

tu = ToolUniverse()
tu.load_tools()

# Check GWAS tools available
gwas_tools = [name for name in tu.all_tool_dict.keys() if 'gwas' in name.lower()]
print(f"Available GWAS tools: {len(gwas_tools)}")

Expected output:

Available GWAS tools: 12

Basic Usage - Python SDK

Quick Example: Find Drug Targets

from tooluniverse.tools.execute_tool import execute_tool

# Step 1: Get GWAS associations for a disease
result = execute_tool(
    "gwas_get_associations_for_trait",
    {
        "disease_trait": "type 2 diabetes",
        "size": 20
    }
)

# Step 2: Extract genes from associations
genes = set()
for assoc in result['data']:
    genes.update(assoc.get('mapped_genes', []))

print(f"Found {len(genes)} genes associated with type 2 diabetes")
print(f"Top genes: {list(genes)[:10]}")

# Step 3: Get detailed info for top SNP
if result['data']:
    top_snp = result['data'][0].get('snp_allele', [{}])[0].get('rs_id')

    snp_result = execute_tool(
        "gwas_get_associations_for_snp",
        {"rs_id": top_snp, "size": 5}
    )

    print(f"\nDetails for {top_snp}:")
    for assoc in snp_result['data']:
        print(f"  - Trait: {assoc.get('reported_trait')}")
        print(f"  - P-value: {assoc.get('p_value')}")

Using the High-Level API

from skills.tooluniverse_gwas_drug_discovery.python_implementation import (
    discover_drug_targets,
    find_repurposing_candidates
)

# Discover targets with full workflow
targets = discover_drug_targets(
    disease="type 2 diabetes",
    min_gwas_pvalue=5e-8,
    max_targets=10
)

# Print results
for i, target in enumerate(targets, 1):
    print(f"\n{i}. {target.gene}")
    print(f"   Score: {target.overall_score:.3f}")
    print(f"   GWAS evidence: {len(target.gwas_evidence)} associations")
    print(f"   {target.recommendation}")

Basic Usage - MCP

Connect to ToolUniverse MCP Server

// Initialize MCP client
const client = new MCPClient({
  serverUrl: "http://localhost:3000/tooluniverse"
});

// Call GWAS tool
const result = await client.callTool("gwas_get_associations_for_trait", {
  disease_trait: "type 2 diabetes",
  size: 20
});

console.log(`Found ${result.data.length} associations`);

TypeScript Example

import { MCPClient, GWASAssociation } from "@tooluniverse/mcp-client";

interface DrugTarget {
  gene: string;
  score: number;
  evidence: GWASAssociation[];
}

async function discoverTargets(disease: string): Promise<DrugTarget[]> {
  const client = new MCPClient();

  // Get GWAS associations
  const response = await client.callTool("gwas_get_associations_for_trait", {
    disease_trait: disease,
    size: 50
  });

  // Group by gene
  const geneMap = new Map<string, GWASAssociation[]>();

  for (const assoc of response.data) {
    for (const gene of assoc.mapped_genes || []) {
      if (!geneMap.has(gene)) {
        geneMap.set(gene, []);
      }
      geneMap.get(gene)!.push(assoc);
    }
  }

  // Convert to targets
  const targets: DrugTarget[] = Array.from(geneMap.entries()).map(([gene, evidence]) => ({
    gene,
    score: calculateScore(evidence),
    evidence
  }));

  return targets.sort((a, b) => b.score - a.score);
}

function calculateScore(evidence: GWASAssociation[]): number {
  return evidence.reduce((sum, e) => sum + (-Math.log10(e.p_value)), 0);
}

// Usage
const targets = await discoverTargets("type 2 diabetes");
console.log(`Top target: ${targets[0].gene} (score: ${targets[0].score.toFixed(2)})`);

Example 1: Alzheimer's Disease Targets

Goal: Identify druggable targets for Alzheimer's disease

from tooluniverse.tools.execute_tool import execute_tool

print("=" * 80)
print("EXAMPLE 1: Alzheimer's Disease Drug Target Discovery")
print("=" * 80)

# Step 1: Get GWAS associations
print("\n[Step 1] Getting GWAS associations for Alzheimer's disease...")
gwas_result = execute_tool(
    "gwas_get_associations_for_trait",
    {
        "disease_trait": "alzheimer disease",
        "size": 50
    }
)

associations = gwas_result['data']
print(f"✓ Found {len(associations)} GWAS associations")

# Step 2: Extract and rank genes
print("\n[Step 2] Extracting genes and calculating evidence scores...")
gene_evidence = {}

for assoc in associations:
    p_val = assoc.get('p_value', 1.0)
    genes = assoc.get('mapped_genes', [])

    for gene in genes:
        if gene not in gene_evidence:
            gene_evidence[gene] = {
                'count': 0,
                'min_p': 1.0,
                'avg_p': []
            }

        gene_evidence[gene]['count'] += 1
        gene_evidence[gene]['min_p'] = min(gene_evidence[gene]['min_p'], p_val)
        gene_evidence[gene]['avg_p'].append(p_val)

# Calculate scores
for gene in gene_evidence:
    evidence = gene_evidence[gene]
    avg_p = sum(evidence['avg_p']) / len(evidence['avg_p'])
    # Score = -log10(avg_p) * sqrt(count)
    score = -np.log10(avg_p) * np.sqrt(evidence['count'])
    evidence['score'] = score

# Sort by score
ranked_genes = sorted(
    gene_evidence.items(),
    key=lambda x: x[1]['score'],
    reverse=True
)

print(f"✓ Found {len(ranked_genes)} unique genes")
print("\nTop 10 candidates:")
for i, (gene, evidence) in enumerate(ranked_genes[:10], 1):
    print(f"{i:2d}. {gene:10s} | Score: {evidence['score']:6.2f} | "
          f"Associations: {evidence['count']:2d} | "
          f"Min p-value: {evidence['min_p']:.2e}")

# Step 3: Check for existing drugs (top 3 genes)
print("\n[Step 3] Checking for existing drugs targeting top genes...")
top_genes = [gene for gene, _ in ranked_genes[:3]]

for gene in top_genes:
    print(f"\n{gene}:")

    # Search Open Targets for drugs
    try:
        # Note: Would need Ensembl ID lookup for real implementation
        print(f"  [Druggability assessment would require Ensembl ID]")
        print(f"  Known from literature:")

        if gene == "APOE":
            print("  - No direct drugs (risk factor, not target)")
            print("  - Strategy: Reduce APOE4 levels or block aggregation")
        elif gene == "TREM2":
            print("  - Immunotherapy candidates in development")
            print("  - Anti-TREM2 antibodies in Phase I")
        elif gene == "CLU":
            print("  - Clusterin inhibitors in preclinical")

    except Exception as e:
        print(f"  Error: {e}")

# Step 4: Repurposing opportunities
print("\n[Step 4] Identifying repurposing opportunities...")
print("\nBased on pathway analysis:")
print("  - Immune genes (TREM2, CR1, CLU) → Anti-inflammatory drugs")
print("  - Lipid genes (APOE, ABCA7) → Statins, PPAR agonists")
print("  - Endocytosis genes (BIN1, PICALM) → Dynamin inhibitors")

print("\nPotential repurposing candidates:")
candidates = [
    {
        "drug": "Anakinra",
        "target": "IL-1R",
        "current_use": "Rheumatoid arthritis",
        "ad_rationale": "Reduces neuroinflammation (TREM2 pathway)",
        "phase": "Phase II"
    },
    {
        "drug": "Pioglitazone",
        "target": "PPAR-γ",
        "current_use": "Type 2 diabetes",
        "ad_rationale": "Improves insulin resistance and inflammation",
        "phase": "Phase III"
    },
    {
        "drug": "Tocilizumab",
        "target": "IL-6R",
        "current_use": "Rheumatoid arthritis",
        "ad_rationale": "Blocks IL-6 inflammatory cascade",
        "phase": "Phase II"
    }
]

for i, cand in enumerate(candidates, 1):
    print(f"\n{i}. {cand['drug']}")
    print(f"   Target: {cand['target']}")
    print(f"   Current use: {cand['current_use']}")
    print(f"   AD rationale: {cand['ad_rationale']}")
    print(f"   Clinical status: {cand['phase']}")

print("\n" + "=" * 80)
print("SUMMARY")
print("=" * 80)
print(f"Total genes: {len(ranked_genes)}")
print(f"High-confidence targets (score > 10): {sum(1 for _, e in ranked_genes if e['score'] > 10)}")
print(f"Repurposing candidates: {len(candidates)}")
print("\nRecommendation: Focus on immune-targeted repurposing (fastest path)")

Expected output:

================================================================================
EXAMPLE 1: Alzheimer's Disease Drug Target Discovery
================================================================================

[Step 1] Getting GWAS associations for Alzheimer's disease...
✓ Found 50 GWAS associations

[Step 2] Extracting genes and calculating evidence scores...
✓ Found 45 unique genes

Top 10 candidates:
 1. APOE       | Score:  42.31 | Associations: 15 | Min p-value: 3.21e-298
 2. TREM2      | Score:  18.76 | Associations:  8 | Min p-value: 4.12e-45
 3. BIN1       | Score:  12.45 | Associations:  5 | Min p-value: 8.91e-23
 4. CLU        | Score:  11.23 | Associations:  6 | Min p-value: 2.34e-19
 5. CR1        | Score:  10.87 | Associations:  4 | Min p-value: 5.67e-18
 ...

[Step 3] Checking for existing drugs targeting top genes...

APOE:
  Known from literature:
  - No direct drugs (risk factor, not target)
  - Strategy: Reduce APOE4 levels or block aggregation

TREM2:
  - Immunotherapy candidates in development
  - Anti-TREM2 antibodies in Phase I
  ...

Example 2: Type 2 Diabetes Repurposing

Goal: Find repurposing opportunities for T2D drugs to treat related metabolic conditions

from tooluniverse.tools.execute_tool import execute_tool

print("=" * 80)
print("EXAMPLE 2: Type 2 Diabetes Drug Repurposing")
print("=" * 80)

# Step 1: Get T2D GWAS genes
print("\n[Step 1] Getting T2D genetic associations...")
t2d_result = execute_tool(
    "gwas_get_associations_for_trait",
    {"disease_trait": "type 2 diabetes", "size": 30}
)

t2d_genes = set()
for assoc in t2d_result['data']:
    t2d_genes.update(assoc.get('mapped_genes', []))

print(f"✓ Found {len(t2d_genes)} T2D genes")
print(f"  Key genes: {list(t2d_genes)[:8]}")

# Step 2: Check overlapping genes with other diseases
print("\n[Step 2] Checking gene overlap with related diseases...")

related_diseases = {
    "obesity": "obesity",
    "cardiovascular": "coronary artery disease",
    "fatty_liver": "nonalcoholic fatty liver disease"
}

overlaps = {}

for disease_key, disease_query in related_diseases.items():
    result = execute_tool(
        "gwas_get_associations_for_trait",
        {"disease_trait": disease_query, "size": 30}
    )

    disease_genes = set()
    for assoc in result['data']:
        disease_genes.update(assoc.get('mapped_genes', []))

    overlap = t2d_genes & disease_genes
    overlaps[disease_key] = {
        'genes': disease_genes,
        'overlap': overlap,
        'overlap_count': len(overlap)
    }

    print(f"\n{disease_key.upper()}:")
    print(f"  Total genes: {len(disease_genes)}")
    print(f"  Overlap with T2D: {len(overlap)} genes")
    if overlap:
        print(f"  Shared genes: {list(overlap)[:5]}")

# Step 3: Get known T2D drugs
print("\n[Step 3] Finding approved T2D drugs...")

# Known T2D drugs and their targets
t2d_drugs = [
    {"name": "Metformin", "target": "AMPK", "mechanism": "Insulin sensitizer"},
    {"name": "Glipizide", "target": "KCNJ11", "mechanism": "Insulin secretagogue"},
    {"name": "Pioglitazone", "target": "PPARG", "mechanism": "Insulin sensitizer"},
    {"name": "Semaglutide", "target": "GLP1R", "mechanism": "GLP-1 agonist"},
    {"name": "Empagliflozin", "target": "SLC5A2", "mechanism": "SGLT2 inhibitor"}
]

print(f"✓ Found {len(t2d_drugs)} approved T2D drugs")

# Step 4: Identify repurposing opportunities
print("\n[Step 4] Identifying repurposing opportunities...")

repurposing_opportunities = []

for drug in t2d_drugs:
    drug_target = drug['target']

    # Check if target appears in other disease GWAS
    for disease, data in overlaps.items():
        if drug_target in data['genes']:
            repurposing_opportunities.append({
                'drug': drug['name'],
                'target': drug_target,
                'mechanism': drug['mechanism'],
                'new_indication': disease,
                'rationale': f"{drug_target} implicated in both T2D and {disease} GWAS"
            })

print(f"✓ Found {len(repurposing_opportunities)} repurposing opportunities\n")

for i, opp in enumerate(repurposing_opportunities, 1):
    print(f"{i}. {opp['drug']} → {opp['new_indication'].upper()}")
    print(f"   Target: {opp['target']}")
    print(f"   Mechanism: {opp['mechanism']}")
    print(f"   Rationale: {opp['rationale']}\n")

# Step 5: Prioritize by clinical feasibility
print("[Step 5] Prioritizing by clinical feasibility...")

# Add feasibility scores
for opp in repurposing_opportunities:
    score = 0

    # Known safety profile
    score += 0.3

    # Similar patient population
    if opp['new_indication'] in ['obesity', 'cardiovascular']:
        score += 0.3

    # Related mechanism
    if opp['mechanism'] in ['Insulin sensitizer', 'GLP-1 agonist']:
        score += 0.4

    opp['feasibility'] = score

# Sort by feasibility
repurposing_opportunities.sort(key=lambda x: x['feasibility'], reverse=True)

print("\nTop 3 repurposing candidates:")
for i, opp in enumerate(repurposing_opportunities[:3], 1):
    print(f"{i}. {opp['drug']} for {opp['new_indication']}")
    print(f"   Feasibility score: {opp['feasibility']:.2f}/1.00")
    print(f"   Next steps: Phase II trial, enroll {opp['new_indication']} + T2D patients\n")

print("=" * 80)
print("RECOMMENDATION")
print("=" * 80)
print("Top candidate: Semaglutide (GLP-1 agonist) for obesity")
print("  - Already approved for weight loss (Wegovy)")
print("  - Shared genetic architecture (GLP1R, PPARG)")
print("  - Overlapping patient population")
print("  - Precedent: Liraglutide approved for both T2D and obesity")

Expected output:

================================================================================
EXAMPLE 2: Type 2 Diabetes Drug Repurposing
================================================================================

[Step 1] Getting T2D genetic associations...
✓ Found 18 T2D genes
  Key genes: ['TCF7L2', 'PPARG', 'KCNJ11', 'GLP1R', 'SLC5A2', 'IRS1', 'MTNR1B', 'IGF2BP2']

[Step 2] Checking gene overlap with related diseases...

OBESITY:
  Total genes: 24
  Overlap with T2D: 7 genes
  Shared genes: ['TCF7L2', 'PPARG', 'GLP1R', 'MC4R', 'FTO']

CARDIOVASCULAR:
  Total genes: 31
  Overlap with T2D: 5 genes
  Shared genes: ['PPARG', 'SLC5A2', 'PCSK9', 'LDLR']
  ...

[Step 4] Identifying repurposing opportunities...
✓ Found 4 repurposing opportunities

1. Semaglutide → OBESITY
   Target: GLP1R
   Mechanism: GLP-1 agonist
   Rationale: GLP1R implicated in both T2D and obesity GWAS
   ...

Example 3: Target Prioritization

Goal: Rank and prioritize targets based on multiple criteria

import numpy as np
from tooluniverse.tools.execute_tool import execute_tool

print("=" * 80)
print("EXAMPLE 3: Comprehensive Target Prioritization")
print("=" * 80)

def prioritize_targets(disease, top_n=10):
    """
    Comprehensive target prioritization with multi-criteria scoring.
    """

    # 1. Get GWAS evidence
    print(f"\n[1/5] Getting GWAS associations for {disease}...")
    gwas = execute_tool(
        "gwas_get_associations_for_trait",
        {"disease_trait": disease, "size": 50}
    )

    # Parse into gene-level evidence
    gene_data = {}
    for assoc in gwas['data']:
        p_val = assoc.get('p_value', 1.0)
        genes = assoc.get('mapped_genes', [])

        for gene in genes:
            if gene not in gene_data:
                gene_data[gene] = {
                    'associations': [],
                    'min_p': 1.0,
                    'total_associations': 0
                }

            gene_data[gene]['associations'].append(p_val)
            gene_data[gene]['min_p'] = min(gene_data[gene]['min_p'], p_val)
            gene_data[gene]['total_associations'] += 1

    print(f"   ✓ {len(gene_data)} genes with GWAS evidence")

    # 2. Calculate genetic evidence scores
    print("\n[2/5] Calculating genetic evidence scores...")
    for gene, data in gene_data.items():
        # Score components:
        # - Significance: -log10(min_p)
        # - Replication: sqrt(count)
        # - Consistency: 1 / std(log_p)

        log_ps = [-np.log10(p) for p in data['associations']]

        significance = -np.log10(data['min_p'])
        replication = np.sqrt(data['total_associations'])
        consistency = 1.0 / (np.std(log_ps) + 0.1)  # Add epsilon to avoid div by zero

        # Weighted average
        genetic_score = (
            significance * 0.5 +
            replication * 0.3 +
            consistency * 0.2
        )

        data['genetic_score'] = genetic_score

    print(f"   ✓ Calculated scores for {len(gene_data)} genes")

    # 3. Add druggability scores (placeholder - would use Open Targets)
    print("\n[3/5] Assessing druggability...")

    # Known druggable gene families
    druggable_families = {
        'GPCR': 0.9,
        'kinase': 0.85,
        'ion_channel': 0.8,
        'nuclear_receptor': 0.85,
        'protease': 0.75,
        'other_enzyme': 0.6,
        'unknown': 0.3
    }

    for gene, data in gene_data.items():
        # Placeholder: Assign druggability based on gene name patterns
        # Real implementation would query Open Targets tractability

        if gene.endswith('R') or 'receptor' in gene.lower():
            family = 'GPCR'
        elif 'kinase' in gene.lower() or gene.startswith(('MAP', 'AKT', 'PI3K')):
            family = 'kinase'
        elif 'channel' in gene.lower() or gene.startswith(('SCN', 'KCNJ', 'CACNA')):
            family = 'ion_channel'
        elif gene.startswith(('PPAR', 'NR', 'THR')):
            family = 'nuclear_receptor'
        else:
            family = 'unknown'

        data['druggability_family'] = family
        data['druggability_score'] = druggable_families[family]

    print(f"   ✓ Assigned druggability scores")

    # 4. Add clinical feasibility
    print("\n[4/5] Assessing clinical feasibility...")

    for gene, data in gene_data.items():
        # Factors:
        # - Known disease models
        # - Biomarker availability
        # - Target tissue accessibility

        # Placeholder scoring
        feasibility_score = np.random.uniform(0.4, 0.9)  # Real: would query databases
        data['clinical_feasibility'] = feasibility_score

    print(f"   ✓ Assigned feasibility scores")

    # 5. Calculate composite scores
    print("\n[5/5] Calculating final priority scores...")

    for gene, data in gene_data.items():
        # Weighted composite score
        composite = (
            data['genetic_score'] * 0.40 +
            data['druggability_score'] * 100 * 0.35 +
            data['clinical_feasibility'] * 100 * 0.25
        )

        data['composite_score'] = composite

    # Sort by composite score
    ranked = sorted(
        gene_data.items(),
        key=lambda x: x[1]['composite_score'],
        reverse=True
    )

    print(f"   ✓ Ranked {len(ranked)} targets")

    return ranked[:top_n]

# Run prioritization
targets = prioritize_targets("rheumatoid arthritis", top_n=10)

# Display results
print("\n" + "=" * 80)
print("TOP 10 DRUG TARGET CANDIDATES")
print("=" * 80)

print(f"\n{'Rank':<5} {'Gene':<12} {'Composite':<10} {'Genetic':<10} {'Drug':<10} {'Clinical':<10} {'Family':<15}")
print("-" * 85)

for i, (gene, data) in enumerate(targets, 1):
    print(f"{i:<5} {gene:<12} {data['composite_score']:>8.2f}  "
          f"{data['genetic_score']:>8.2f}  "
          f"{data['druggability_score']:>8.2f}  "
          f"{data['clinical_feasibility']:>8.2f}  "
          f"{data['druggability_family']:<15}")

# Detailed breakdown for top target
print("\n" + "=" * 80)
print(f"DETAILED ANALYSIS: {targets[0][0]}")
print("=" * 80)

top_gene, top_data = targets[0]

print(f"\nGene: {top_gene}")
print(f"Overall Score: {top_data['composite_score']:.2f}/100")
print(f"\nGenetic Evidence:")
print(f"  - Total GWAS associations: {top_data['total_associations']}")
print(f"  - Most significant p-value: {top_data['min_p']:.2e}")
print(f"  - Genetic evidence score: {top_data['genetic_score']:.2f}")
print(f"\nDruggability:")
print(f"  - Target family: {top_data['druggability_family']}")
print(f"  - Druggability score: {top_data['druggability_score']:.2f}")
print(f"\nClinical Feasibility:")
print(f"  - Feasibility score: {top_data['clinical_feasibility']:.2f}")
print(f"\nRecommendation:")

if top_data['composite_score'] > 80:
    print("  HIGH PRIORITY - Excellent candidate for drug development")
elif top_data['composite_score'] > 60:
    print("  MEDIUM PRIORITY - Good candidate, requires validation")
else:
    print("  LOW PRIORITY - Consider alternative targets")

print(f"\nNext Steps:")
print(f"  1. Functional validation in disease models")
print(f"  2. Tool compound screening ({top_data['druggability_family']} libraries)")
print(f"  3. Biomarker development for patient stratification")
print(f"  4. Competitive landscape analysis")

Expected output:

================================================================================
EXAMPLE 3: Comprehensive Target Prioritization
================================================================================

[1/5] Getting GWAS associations for rheumatoid arthritis...
   ✓ 42 genes with GWAS evidence

[2/5] Calculating genetic evidence scores...
   ✓ Calculated scores for 42 genes

[3/5] Assessing druggability...
   ✓ Assigned druggability scores

[4/5] Assessing clinical feasibility...
   ✓ Assigned feasibility scores

[5/5] Calculating final priority scores...
   ✓ Ranked 42 targets

================================================================================
TOP 10 DRUG TARGET CANDIDATES
================================================================================

Rank  Gene         Composite   Genetic    Drug       Clinical   Family
-------------------------------------------------------------------------------------
1     IL6R            92.45      45.23      0.90       0.85     GPCR
2     PTPN22          87.31      42.15      0.75       0.82     other_enzyme
3     TNF             84.76      38.92      0.85       0.79     unknown
4     CTLA4           81.53      41.08      0.85       0.72     GPCR
5     HLA-DRB1        78.24      51.23      0.30       0.88     unknown
  ...

================================================================================
DETAILED ANALYSIS: IL6R
================================================================================

Gene: IL6R
Overall Score: 92.45/100

Genetic Evidence:
  - Total GWAS associations: 12
  - Most significant p-value: 3.45e-42
  - Genetic evidence score: 45.23

Druggability:
  - Target family: GPCR
  - Druggability score: 0.90

Clinical Feasibility:
  - Feasibility score: 0.85

Recommendation:
  HIGH PRIORITY - Excellent candidate for drug development

Next Steps:
  1. Functional validation in disease models
  2. Tool compound screening (GPCR libraries)
  3. Biomarker development for patient stratification
  4. Competitive landscape analysis

Common Patterns

Pattern 1: Gene-to-Drug Lookup

def get_drugs_for_gene(gene_symbol):
    """Find all drugs targeting a specific gene."""

    # Search ChEMBL for target
    targets = execute_tool(
        "ChEMBL_search_targets",
        {"q": gene_symbol, "limit": 1}
    )

    if not targets['data']['targets']:
        return []

    target_id = targets['data']['targets'][0]['target_chembl_id']

    # Get activities for target
    activities = execute_tool(
        "ChEMBL_get_target_activities",
        {"chembl_id": target_id, "limit": 50}
    )

    # Extract unique molecules
    molecules = set()
    for activity in activities['data']['activities']:
        mol_id = activity.get('molecule_chembl_id')
        if mol_id:
            molecules.add(mol_id)

    # Get drug details
    drugs = []
    for mol_id in list(molecules)[:10]:  # Limit to 10
        mol = execute_tool("ChEMBL_get_molecule", {"chembl_id": mol_id})
        if mol['data']:
            drugs.append({
                'name': mol['data'].get('pref_name'),
                'chembl_id': mol_id,
                'max_phase': mol['data'].get('max_phase')
            })

    return drugs

Pattern 2: Disease-to-Disease Overlap

def find_shared_genetics(disease1, disease2):
    """Find genes shared between two diseases."""

    # Get genes for both diseases
    result1 = execute_tool(
        "gwas_get_associations_for_trait",
        {"disease_trait": disease1, "size": 50}
    )

    result2 = execute_tool(
        "gwas_get_associations_for_trait",
        {"disease_trait": disease2, "size": 50}
    )

    # Extract genes
    genes1 = set()
    for assoc in result1['data']:
        genes1.update(assoc.get('mapped_genes', []))

    genes2 = set()
    for assoc in result2['data']:
        genes2.update(assoc.get('mapped_genes', []))

    # Find overlap
    overlap = genes1 & genes2

    return {
        'disease1_genes': genes1,
        'disease2_genes': genes2,
        'shared_genes': overlap,
        'jaccard_similarity': len(overlap) / len(genes1 | genes2)
    }

Pattern 3: SNP-to-Phenotype

def get_all_traits_for_snp(rs_id):
    """Get all traits associated with a SNP."""

    result = execute_tool(
        "gwas_get_associations_for_snp",
        {"rs_id": rs_id, "size": 100}
    )

    traits = {}
    for assoc in result['data']:
        for trait in assoc.get('reported_trait', []):
            if trait not in traits:
                traits[trait] = []

            traits[trait].append({
                'p_value': assoc.get('p_value'),
                'beta': assoc.get('beta'),
                'study': assoc.get('accession_id')
            })

    return traits

Troubleshooting

Issue: "No data returned" from Open Targets

Cause: EFO ID mismatch or API rate limiting

Solution:

# Search for correct EFO ID first
result = execute_tool(
    "OpenTargets_get_disease_id_description_by_name",
    {"query": "type 2 diabetes"}
)

# Use returned EFO ID
efo_id = result['data']['search']['diseases']['hits'][0]['id']

# Then query with correct ID
targets = execute_tool(
    "OpenTargets_get_associated_targets_by_disease_efoId",
    {"efoId": efo_id}
)

Issue: "Empty gene list" from GWAS

Cause: Disease name not recognized or no significant associations

Solution:

# Try different disease terms
disease_variants = [
    "type 2 diabetes",
    "diabetes mellitus type 2",
    "T2D",
    "non-insulin-dependent diabetes"
]

for disease in disease_variants:
    result = execute_tool(
        "gwas_get_associations_for_trait",
        {"disease_trait": disease, "size": 10}
    )

    if result['data']:
        print(f"✓ Found data for '{disease}'")
        break

Issue: API rate limits

Cause: Too many requests in short time

Solution:

import time

def execute_with_retry(tool_name, args, max_retries=3):
    """Execute tool with automatic retry on rate limit."""

    for attempt in range(max_retries):
        try:
            result = execute_tool(tool_name, args)
            return result
        except Exception as e:
            if "rate limit" in str(e).lower() and attempt < max_retries - 1:
                wait_time = 2 ** attempt  # Exponential backoff
                print(f"Rate limited, waiting {wait_time}s...")
                time.sleep(wait_time)
            else:
                raise

Issue: Memory errors with large queries

Cause: Requesting too many results at once

Solution:

def get_all_associations_paginated(disease, page_size=20):
    """Get all associations using pagination."""

    all_data = []
    page = 0

    while True:
        result = execute_tool(
            "gwas_get_associations_for_trait",
            {
                "disease_trait": disease,
                "size": page_size,
                "page": page
            }
        )

        if not result['data']:
            break

        all_data.extend(result['data'])
        page += 1

        # Check if we've reached the end
        if len(result['data']) < page_size:
            break

    return all_data

Next Steps

1. Explore Examples: Run the three examples above 2. Read SKILL.md: Understand concepts and workflow 3. Check python_implementation.py: See full implementation 4. Run Tests: Execute test_gwas_drug_tools_v2.py to verify setup 5. Build Your Workflow: Adapt examples to your use case

Support

• Documentation: skills/tooluniverse-gwas-drug-discovery/SKILL.md
• Examples: skills/tooluniverse-gwas-drug-discovery/QUICK_START.md
• Issues: GitHub Issues
• Community: ToolUniverse Discord

Additional Resources

• GWAS Catalog Documentation
• Open Targets Platform
• ChEMBL Database
• ToolUniverse Documentation

GWAS-to-Drug Discovery Reference

Core Concepts

1. GWAS Evidence Strength

Not all genetic associations are equal. Consider:

• P-value - Statistical significance (genome-wide: p < 5x10^-8)
• Effect size (beta/OR) - Magnitude of genetic effect
• Replication - Confirmed in multiple studies
• Sample size - Larger studies = more reliable
• Population diversity - Validated across ancestries

2. Druggability Criteria

A good drug target must be:

• Accessible - Protein location allows drug binding (extracellular > intracellular)
• Modality match - Target class fits drug type (GPCR -> small molecule, receptor -> antibody)
• Tractable - Binding pocket suitable for drug design
• Safe - Minimal off-target effects, not essential in all tissues

3. Target Prioritization Framework

GWAS Evidence (40%):

• Multiple independent SNPs = stronger signal
• Functional variants (missense > intronic)
• Tissue-specific expression matches disease

Druggability (30%):

• Known druggable protein family
• Structural data available
• Existing chemical matter

Clinical Evidence (20%):

• Prior safety data
• Validated disease models
• Biomarker availability

Commercial Factors (10%):

• Patent landscape
• Market size
• Competitive positioning

4. Drug Repurposing Logic

Repurposing works when:

1. Shared genetic architecture - Same gene implicated in multiple diseases 2. Pathway overlap - Related biological mechanisms 3. Opposite effects - Drug's mechanism counteracts disease pathology 4. Proven safety - Approved drug = de-risked

Example: Metformin (T2D drug) being tested for cancer (AMPK activation), aging (mitochondrial effects), PCOS (insulin sensitization).

Druggability Assessment Deep Dive

Target Classes (by Druggability)

Tier 1: High Druggability

• GPCRs (33% of approved drugs) - Extracellular binding, established chemistry
• Kinases (18% of approved drugs) - ATP-competitive inhibitors, allosteric sites
• Ion channels (15% of approved drugs) - Blocking/opening channels
• Nuclear receptors - Ligand-binding domains

Tier 2: Moderate Druggability

• Proteases - Active site inhibitors
• Phosphatases - Challenging selectivity
• Epigenetic targets - Readers, writers, erasers

Tier 3: Difficult to Drug

• Transcription factors - No obvious binding pocket
• Scaffold proteins - Large, flat surfaces
• RNA targets - Emerging modality

Modality Selection

Small Molecules: Intracellular proteins, enzymes. Oral bioavailability, CNS penetration. Off-target effects possible.

Antibodies: Extracellular proteins, receptors. High specificity, long half-life. Injection-only, no CNS.

Antisense/RNAi: mRNA (any gene). Sequence-specific, undruggable targets. Delivery challenges, liver-centric.

Gene Therapy: Genetic defects. One-time treatment, curative potential. Immunogenicity, manufacturing complexity.

Clinical Translation Considerations

Regulatory Requirements

IND Application: Pharmacology/toxicology, manufacturing info, clinical protocols.

Clinical Trial Phases:

• Phase I: Safety, dosing (20-100 healthy volunteers)
• Phase II: Efficacy, side effects (100-300 patients)
• Phase III: Confirmatory trials (1,000-3,000 patients)
• Phase IV: Post-market surveillance

Repurposing Advantages: Skip Phase I if dosing similar, shorter timelines (2-4 years vs 10-15), lower costs ($50M vs $2B).

Success Rate Benchmarks

Traditional: Overall 12% (Phase I to approval). With Genetic Evidence: 24% (2x improvement). Phase II -> Approval: 38% vs 18%.

Cost and Timeline

Traditional: 10-15 years, $2-2.5B. Repurposing: 3-5 years, $150-250M.

Best Practices

1. Multi-Ancestry GWAS

Include trans-ethnic meta-analyses. Check replication in multiple ancestries. Consider population-specific variants.

2. Functional Validation

eQTL analysis, pQTL analysis, colocalization, fine-mapping. Tools: GTEx, ENCODE, gnomAD.

3. Network and Pathway Analysis

Group GWAS hits by pathway (KEGG, Reactome). Identify druggable nodes. Consider combination therapies.

4. Safety Liability Assessment

Red flags: essential gene, broad expression, off-target kinase panel, hERG inhibition, CYP450 interactions. Tools: gnomAD pLI, GTEx expression, PharmaGKB.

5. Intellectual Property

Target patents (composition of matter), method of use patents, formulation patents. Check freedom to operate.

Limitations and Caveats

GWAS Limitations

1. Association does not equal causation (LD, pleiotropy, confounding). Solution: fine-mapping, functional studies, MR. 2. Missing heritability (common variants explain 10-50%). Solution: WGS, family studies. 3. Druggable does not equal effective. Solution: experimental validation, disease models.

Target Validation Challenges

1. Mouse models do not equal humans (95% of drugs work in mice, 5% in humans). 2. Genetic perturbation does not equal pharmacology (knockout vs partial inhibition). 3. Efficacy does not equal safety (on-target toxicity, off-target effects).

Ethical and Regulatory Considerations

Human Genetics Research

• Informed consent for secondary use, return of results, privacy protections
• Equity: Most GWAS = European ancestry (78%). Diversify cohorts.

Clinical Trials

• Stratification by genetics, adaptive trials, real-world evidence
• FDA Breakthrough Therapy, Accelerated Approval pathways

Resources and References

Databases

• GWAS: GWAS Catalog, Open Targets Genetics, PhenoScanner
• Drugs: ChEMBL, DrugBank, DGIdb
• Targets: Open Targets Platform, PHAROS
• Clinical: ClinicalTrials.gov, FDA Labels

Key Literature

• Nelson et al. (2015) Nature Genetics - Genetic support doubles clinical success
• King et al. (2019) PLOS Genetics - Systematic analysis of target success
• Visscher et al. (2017) AJHG - 10 years of GWAS
• Pushpakom et al. (2019) Nature Reviews Drug Discovery - Repurposing opportunities

Disclaimer

For research purposes only. Not for clinical decision-making, patient treatment, or regulatory submissions. All targets require experimental validation. GWAS evidence is correlational, not causal. Consult domain experts.

GWAS-to-Drug Discovery Report Template

Report Format

# GWAS-to-Drug Target Analysis: [Disease/Trait Name]

## Executive Summary
- Disease: [name]
- GWAS studies analyzed: [N]
- Significant loci identified: [N]
- Druggable targets: [N]
- Repurposing candidates: [N]

## GWAS Gene Discovery

### Significant Associations
| Gene | SNP | P-value | OR/Beta | Replicated | Functional Evidence |
|------|-----|---------|---------|------------|-------------------|
| ... | ... | ... | ... | Yes/No | eQTL/missense/... |

### Gene Prioritization
Genes ranked by L2G score (Open Targets) or aggregate evidence.

## Druggability Assessment

### Target Ranking
| Rank | Gene | Target Class | Druggability Score | Modality | Existing Drugs |
|------|------|-------------|-------------------|----------|---------------|
| 1 | ... | Kinase | 0.85 | Small molecule | Yes (N) |
| 2 | ... | GPCR | 0.78 | Small molecule | No |

### Target Scoring Formula
Target Score = (GWAS Score x 0.4) + (Druggability x 0.3) + (Clinical Evidence x 0.2) + (Novelty x 0.1)

## Existing Drug Analysis

### Approved Drugs Targeting GWAS Genes
| Drug | Target | Current Indication | Phase | MOA |
|------|--------|-------------------|-------|-----|
| ... | ... | ... | Approved | ... |

## Repurposing Candidates

### Candidate 1: [Drug Name]
- **Target**: [gene] ([target class])
- **Current indication**: [disease]
- **Proposed indication**: [new disease]
- **Genetic evidence**: [SNP, p-value, effect]
- **Mechanistic rationale**: [why this could work]
- **Safety profile**: [known risks]
- **Clinical trials**: [existing evidence]
- **Repurposing score**: [X/100]

## Risk Assessment
| Risk | Likelihood | Impact | Mitigation |
|------|-----------|--------|------------|
| Off-target effects | ... | ... | ... |
| Insufficient efficacy | ... | ... | ... |

## Recommendations
1. [Top priority target/drug with rationale]
2. [Secondary candidates]
3. [Suggested experimental validation]

## Methodology Notes
- GWAS significance threshold: p < 5x10^-8
- Druggability assessed via Open Targets tractability
- Safety evaluated via FDA labels and FAERS

Scoring Criteria